skip to content

Yusuf Hamied Department of Chemistry

 

I am now Professor Emeritus, but continue research with several ongoing research grants as Director of Research.

There is a strong interest in the development of novel molecular property calculations and data analysis methods combined with the simulation of biomolecules and materials. Current research interests include drug discovery methods (SAR, simulation of biomolecules and ADME) and molecular data analysis (machine learning, deep learning) as well as drug discovery projects against specific targets. Recent work has seen compounds evaluated in human clinical studies in Addenbrooke's hospital.

 

Career highlights

I gained my Ph.D. (supervisor Prof. Peter Murray-Rust) in X-ray Crystallography, computational chemistry and Organic Synthesis from the University of Stirling.  One of the highlights was the first co-crystallisation of a reactant and product of a chemical reaction in a single crystal. 

As a Senior Research Scientist at the Wellcome Foundation I guided the development of the Computer-aided Molecular Design group. This included Protein Crystallography (the first in a pharmaceutical company), Molecular Transport properties and Electrochemistry.  I designed the GASP and GOLD computer programs which are used extensively in the pharmaceutical industry, I am a co-inventor of Zomig (a drug for migraine) and invented two other compounds at Wellcome that entered Phase-2 clinical development. 

As Vice President for Collaborative Research at Tripos Inc., a biotechnology company in St. Louis Mo. we created the first commercial screening library, Optiverse (100K compounds), and I assisted in setting up three biotechnology companies (Arena Pharmaceuticals, Phase-1 Molecular Toxicology and Signase).  I obtained and directed a significant BBSRC grant with University College London (discovering activators of soluble guanylate cyclise and working with The Technology Partnership to develop the Baseplate robot) and managed collaborative research and contract research in drug discovery with many large Pharmaceutical companies. Two of the research programs resulted in drugs for obesity (lorcaserin) and sleep disorders/alzheimers (nelotanserin).

In 1999 I moved to the University of Cambridge as Founding Director of the Unilever Centre for Molecular Sciences Informatics, a new institute as part of the Chemistry department, now the Centre for Molecular Informatics, part of the Theoretical Group.

I have served on the boards of a number of emerging biotech and technology companies and serve on a number of grant awarding bodies and am a Fellow of Clare College Cambridge. I have been a consultant to many large pharma companies. I have additionally received over £20M in grants over the last ten years, from Wellcome Trust, NHS, EPSRC, BBSRC, DTI, MRC and Pharmaceutical and software companies.

I was elected Professor of Computational Medicine at Imperial College London, and direct several groups working on Big Data projects in diverse areas such as metabonomics, clinical data analysis, imaging (the first imaging of a tumour in 3D using mass spectrometry.

Teaching

Teaching commitments are principally now mentoring and examination.

Lectures

I lecture regularly at conferences, in companies and to  undergraduates and post graduates. e.g. The Gordon Converence on CAMD, 2023 - Plenary Lecture

Environment

The Centre for Molecular Informatics has four research groups, Glen, Goodman, Bender and Colwell.

Further Funding Information

We receive funding from most research councils, the EU, charities and companies. We thank them all and are very grateful to all our funders, particularly Unilever whose generosity founded the Centre for Molecular Informatics.

Publications

Neural Networks and Expert Systems in Molecular Design
DT Manallack, DJ Livingstone, M A‐Razzak, RC Glen
(1994)
293
A fast empirical method for the calculation of molecular polarizability.
RC Glen
– Journal of Computer-Aided Molecular Design
(1994)
8,
457
Quantitative structure chromatography relationships in reversed-phase high performance liquid chromatography: Prediction of retention behaviour using theoretically derived molecular properties
BC CUPID, JK NICHOLSON, P DAVIS, RJ RUANE, ID WILSON, RC GLEN, VS ROSE, CR BEDDELL, JC LINDON
– Chromatographia
(1993)
37,
241
Conformational Flexibility of N-Formylmorpholine Studied Using Variable Temperature13C NMR Spectroscopy and Molecular Dynamics Calculations
SR SALMAN, RD FARRANT, RC GLEN, JC LINDON
– Spectroscopy Letters
(1993)
26,
745
CONFORMATIONAL STUDIES OF A CYCLIC RGD-CONTAINING PEPTIDE ANALOG
PN SANDERSON, RC GLEN, C HEIDE, BD HUDSON, GE TRANTER, PM DOYLE, CJ HARRIS
– JOURNAL OF CELLULAR BIOCHEMISTRY
(1993)
283
SEARCHING DATABASES OF 2-DIMENSIONAL AND 3-DIMENSIONAL CHEMICAL STRUCTURES USING GENETIC ALGORITHMS
G JONES, RD BROWN, DE CLARK, P WILLETT, RC GLEN
– PROCEEDINGS OF THE FIFTH INTERNATIONAL CONFERENCE ON GENETIC ALGORITHMS
(1993)
597
SYNTHESIS AND PHARMACOLOGICAL PROPERTIES OF BW315C AND OTHER INOTROPIC 2-ARYLIMIDAZO[1,2-A]PYRAZINES
P BARRACLOUGH, JW BLACK, D CAMBRIDGE, VP GERSKOWITCH, H GILES, RC GLEN, RAD HULL, R IYER, WR KING, MS NOBBS, P RANDALL, GP SHAH, D STONE, SJ VINE, MV WHITING
– Bioorganic and Medicinal Chemistry Letters
(1993)
3,
509
Molecular recognition using a binary genetic search algorithm.
AW Payne, RC Glen
– Journal of Molecular Graphics and Modelling
(1993)
11,
74
Quantitative structure-metabolism relationships for substituted benzoic acids in the rat. Computational chemistry, NMR spectroscopy and pattern recognition studies.
FY Ghauri, CA Blackledge, RC Glen, BC Sweatman, JC Lindon, CR Beddell, ID Wilson, JK Nicholson
– Biochemical pharmacology
(1992)
44,
1935
Applications of rule-induction in the derivation of quantitative structure-activity relationships
M A-Razzak, RC Glen
– J Comput Aided Mol Des
(1992)
6,
349
  • <
  • 24 of 26
  • >

Research Group

Research Interest Groups

Telephone number

01223 336472

Email address

rcg28@cam.ac.uk